Inactive Instrument

News Exalenz Bioscience Ltd. TEL AVIV STOCK EXCHANGE

Equities

IL0011048688

Summary

Unlock all the news: Be the first to know and act before the market!

Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others.	30/20/30	CI
Meridian Bioscience : Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform	19/20/19	AQ
Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million.	19/20/19	CI
Exalenz Bioscience Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019	14/19/14	CI
Exalenz Bioscience Receives Approval for Commercial Marketing in China for Its Breathid® HP Lab System	25/19/25	CI
Exalenz Bioscience Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	15/18/15	CI
Exalenz Bioscience Ltd Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2018	31/18/31	CI
Exalenz Bioscience Ltd. Announces BreathID®13C-methacetin Breath Test	10/18/10	CI
Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer	30/18/30	CI
Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients	13/18/13	CI
Exalenz Bioscience Ltd Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017; Provides Earnings Guidance for the Year 2018 and Revenue Guidance for the Year 2019	12/18/12	CI
Exalenz Bioscience Announces Positive Clinical Trial Results for the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients	24/18/24	CI
Exalenz Bioscience Ltd Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori Detection	17/17/17	CI
Exalenz Bioscience Plans For Nasdaq IPO	14/17/14	CI
Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States	01/16/01	CI
Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to Use BreathID to Monitor Patients with Cirrhosis Associated with NASH	03/15/03	CI
Exalenz Bioscience Ltd and Galectin Therapeutics, Inc. Receive FDA Approval for Joint Clinical Trial of Second-Stage of GR-MD-02	02/15/02	CI
Exalenz Bioscience Ltd Launches Clinical Study for Breath-Based Detection of Primary Liver Cancer	04/15/04	CI
Exalenz Bioscience Launches Additional Clinical Study of Breath-Based Diagnostic Test	06/15/06	CI
Exalenz Bioscience Ltd. Auditor Raises 'Going Concern' Doubt	26/15/26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Exalenz Bioscience Ltd. TEL AVIV STOCK EXCHANGE

Equities

IL0011048688

Summary

Filters